Search published articles


Showing 3 results for Dyslipidemia
Dyslipidemia in diabetic patients: a cross sectional study in urban population of Yazd, Iran
Rafiei M, Sadr Bafghi Smh, Nasirian M, Namayandeh Sm, Abdoli Am, Sadr Bafghi Sm,
Volume 66, Issue 7 (10-2008)
Abstract

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 !mso]> ject classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui> Background: Atherosclerosis and the side effects thereof are a major cause of mortality and morbidity in diabetic patients. Diabetic dyslipidemia is defined by a decrease in blood levels of HDL cholesterol and increases in triglycerides and LDL cholesterol. Diabetic dyslipidemia is atherogenic, inducing cardiovascular disease in diabetic patients at a frequency that is two to three times greater than that of nondiabetics.
Methods: This study analyzes the data from the first phase of the Yazd Healthy Heart Program, a community intervention project focused on the prevention of cardiovascular disease. Using the cluster sampling method, we analyzed data from 2000 subjects from Yazd, Iran, ranging in age from 20 to 74 years. Clinical and paraclinical data were recorded by trained health providers using a questionnaire with over 700 items.
Results: The most frequent lipid disturbance was TG>150 in 67.1% of the type-II diabetic patients (p<0.000), 54.6% of whom were unaware of their TG level. The mean lipid and TG levels are significantly higher (p<0.000). Furthermore, women as a group have higher mean cholesterol, LDL-C and HDL-C levels than men (p<0.000). Additionally, diabetic patients were more obese than the nondiabetic population. (p<0.000).
Conclusion: The high prevalence of diabetes mellitus in Yazd and hypertriglyceride-mia among diabetics in this city, in addition to the lack of awareness among more than half of these patients about their illness and diagnosis, indicate an urgent need to immediately control dyslipidemia in these high-risk patients.


Effects of simvastatin with or without fenofibrate on echocardiographic findings of patients with coronary artery disease and dyslipidemia: a brief report
Karbasi-Afshar R, Shahmari A, Shafighi N, Saburi A,
Volume 70, Issue 6 (9-2012)
Abstract

Background: Various therapeutic protocols have been recommended for treating dyslipidemia, particularly in patients with coronary artery disease. The purpose of this study was to assess the efficacy of statin use with or without fenofibrate on echocardiographic findings of patients with coronary artery disease and dyslipidemia.
Methods: This clinical trial was conducted on 124 patients with coronary artery disease and dyslipidemia in Baqiyatallah Hospital in Tehran, Iran during 2008 to 2010. The first group of patients (64) received simvastatin (20 mg) and fenofibrate (200 mg) with low lipid diet and exercise while the second group (60) only received simvastatin with low lipid diet and exercise for one year.
Results: The mean age of the participants was 54.3±6.5 years. The first group showed significant changes in lipid profile and left ventricular ejection fraction (LVEF), (P<0.05). Left ventricular diastolic function parameters showed no significant changes in both groups upon 12 months of treatment.
Conclusion: The results of this study show, one-year treatment by simvastatin and fenofibrate can be effective on lipid profiles, and improve LVEF with resultant positive effect on heart function.


The effects of plasma levels of vitamin D3 on insulin resistance and biochemical factors of plasma in patients with type 2 diabetes
Mahboobeh Sadat Hosseini , Mohammad Javad Bahoosh , Gholamhossein Alishiri , Nahid Khalili , Habib Yaribeygi ,
Volume 75, Issue 11 (2-2018)
Abstract
Background: The prevalence of diabetes mellitus due to existence of various factors is growing rapidly. The insulin resistance phenomenon is one of the main underlying causes of this disease, due to various reasons such as a decrease in serum levels of vitamin D3. In this study, we evaluated the relationship between plasma level of vitamin D3 and some other main plasma factors.
Methods: This clinical trial study carried out on type 2 diabetes mellitus subjects who referred to diabetes clinic of Baqiyatallah Hospital in Tehran city during June to September 2016. First demographic data of all patients were collected. Then the blood samples for evaluation of blood glucose, HbA1c, triglyceride, cholesterol, HDL, LDL and vitamin D3 were obtained. Based on plasma level of vitamin D3, diabetic subjects were divided into two separate treatment groups (with and without vitamin D3 deficiency) and then above-mentioned factors were compared between these two groups. Afterward, in group with vitamin D3 deficiency, treatment by vitamin D3 triggered (50000 unit per week for eight weeks orally) until plasma level of vitamin D3 reached above 30 ng/mL. Then, treatment continued by vitamin D3 (50000 Unit per week orally) and calcium (1.5 g/day PO) until 60 days. Finally, the patients were evaluated about fasting blood glucose, HbA1c, HDL, LDL and blood pressure.
Results: In total, 187 subjects (99 men and 88 women) were evaluated in this study. Total hypovitaminose incidence was 0.65% which was higher in subjects with higher body mass index (BMI). Serum content of vitamin D3 and calcium, significantly changed the values of fasting blood sugar (FBS), HbA1c, HDL and TG, but has no significant effects on other factors.
Conclusion: Our results clearly revealed that hypovitaminose vitamin D3 is one of the main factors that can leading to rise in plasma glucose and dyslipidemia occurrence. Also, our data are demonstrated that treatment by vitamin D3 and calcium can modify fasting blood glucose and dyslipidemia in type 2 diabetes mellitus subjects.

Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb